Home / Health / Invivoscribe Launches Advanced MRD NGS Solution
Invivoscribe Launches Advanced MRD NGS Solution
6 Oct
Summary
- Invivoscribe launched the LymphoTrack Flex suite for NGS-based immune receptor MRD testing.
- The solution identifies and tracks gene rearrangements in lymphoid malignancies.
- It offers standardized, high-throughput, and ultra-high sensitivity workflows for oncology.
Invivoscribe has introduced the complete LymphoTrack Flex suite, a new integrated next-generation sequencing (NGS) solution designed for precision diagnostics and measurable residual disease (MRD) testing.
This advanced suite focuses on identifying and tracking immunoglobulin and T-cell receptor gene rearrangements, crucial for understanding lymphoid malignancies. As NGS-based immune receptor MRD analysis transitions into routine oncology research, there is a growing need for standardized, high-throughput, and highly sensitive workflows. LymphoTrack Flex addresses these demands by combining seven molecular targets into one automation-ready process.
The solution provides laboratories with flexibility through its software options: LymphoTrack Software for local analysis and LymphoTrack Enterprise Software for high-throughput, centralized analysis. This allows for scalable testing volumes and consistent molecular tracking of clonal sequences over time, supporting dynamic, MRD-informed treatment approaches.
Invivoscribe's CEO, Jeff Miller, expressed pride in the team, stating the vision is to provide all laboratories with optimized MRD assays, controls, and analysis software through a standardized approach. The company has over thirty years of experience in advancing healthcare with precision diagnostics.
